BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 31006056)

  • 1. Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art.
    Oliveira MD; Mataloto I; Kanavos P
    Eur J Health Econ; 2019 Aug; 20(6):891-918. PubMed ID: 31006056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implications.
    Kriza C; Hanass-Hancock J; Odame EA; Deghaye N; Aman R; Wahlster P; Marin M; Gebe N; Akhwale W; Wachsmuth I; Kolominsky-Rabas PL
    Health Res Policy Syst; 2014 Dec; 12():66. PubMed ID: 25466570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
    Baltussen R; Marsh K; Thokala P; Diaby V; Castro H; Cleemput I; Garau M; Iskrov G; Olyaeemanesh A; Mirelman A; Mobinizadeh M; Morton A; Tringali M; van Til J; Valentim J; Wagner M; Youngkong S; Zah V; Toll A; Jansen M; Bijlmakers L; Oortwijn W; Broekhuizen H
    Value Health; 2019 Nov; 22(11):1283-1288. PubMed ID: 31708065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.
    Campolina AG; Estevez-Diz MDP; Abe JM; de Soárez PC
    PLoS One; 2022; 17(5):e0268584. PubMed ID: 35613115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicriteria decision analysis in health care decision in oncology: a systematic review.
    Campolina AG; Suzumura EA; Hong QN; de Soárez PC
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):365-380. PubMed ID: 34913775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
    Diaby V; Goeree R; Hoch J; Siebert U
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):13-9. PubMed ID: 25267699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment.
    Angelis A; Kanavos P
    Pharmacoeconomics; 2016 May; 34(5):435-46. PubMed ID: 26739955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.
    Angelis A
    MDM Policy Pract; 2018; 3(2):2381468318796218. PubMed ID: 35187241
    [No Abstract]   [Full Text] [Related]  

  • 19. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges.
    Huls SPI; Whichello CL; van Exel J; Uyl-de Groot CA; de Bekker-Grob EW
    Value Health; 2019 Nov; 22(11):1318-1328. PubMed ID: 31708070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.